Please assess the completion status of the following clinical trial:

Trial Title: Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18-64 years of age with a primary diagnosis of PTSD as defined by DSM-IV criteria with associated sleep disturbance~Exclusion Criteria:~* Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception.~* Concurrent use of other psychotropic medications, other than antidepressants at stable dose for at least 4 weeks prior to randomization~* Serious medical illness or instability~* Seizure disorders with the exception of a history of febrile seizures if they occurred during childhood~* Concurrent psychotherapy initiated within one month of randomization or ongoing psychotherapy of any duration directed specifically toward treatment of PTSD and/or sleep disturbance~* Diagnosis of schizophrenia, mental retardation, OCD, organic medical disorders or bipolar disorder, eating disorders in the past 6 months, alcohol or substance abuse in the past 3 months, or dependence within the past 6 months.~* Patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone (Type: EXPERIMENTAL): Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.

Based on this trial design, predict the completion outcome and termination type (if applicable).